Investment
Features
FeesSafety
Academy
More
Pluang+

Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Philip Morris International Inc. (PM) Price & Performance

T-Rex 2X Inverse MSTR Daily Target ETFTrade
Philip Morris International Inc.Trade

Price performance (Past 24H)

Key statistics

T-Rex 2X Inverse MSTR Daily Target ETF vs Philip Morris International Inc. — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.62 (market cap $94.46M), while Philip Morris International Inc. trades at $201 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 3308.3× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Philip Morris International Inc. pays a 3.19% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days and Philip Morris International Inc. for 85 Days on average.

MSTZPM
Market Cap
$94.46M$312.50B
Volume
104,717,7335,517,172
Sector
Leveraged / InverseConsumer Staples
52-Week High
$27.92$200.50
52-Week Low
$2.29$144.33
Typical Hold Time
8 Days85 Days
Enterprise Value
—$355.62B
Dividend Yield
—3.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ trades at $2.58, down 3.01% with bearish technical signals from moving averages. The stock shows mixed momentum with neutral oscillators but negative moving average alignment. Key support sits at $2 with resistance at $3. Recent ETF coverage highlights the stock's inclusion in leveraged/inverse ETF discussions, though specific company fundamentals remain limited in available data.

Outlook remains cautious given technical weakness and limited fundamental visibility. The primary opportunity lies in potential technical rebounds from support levels, while risks include continued bearish momentum and lack of clear fundamental catalysts. Investors should await clearer financial metrics and earnings guidance for directional conviction.

Philip Morris International Inc.

Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.

Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MSTZ
80% Buy20% Sell
Avg holding period · 8 Days
PM
1% Buy99% Sell
Avg holding period · 85 Days

Top news

Latest headlines on both assets

About T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.

Read more on MSTZ →

About Philip Morris International Inc.

Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.

Read more on PM →